Day: February 28, 2025

Audited results of INVL Baltic Farmland group of 2024

Written by Customer Service on February 28, 2025. Posted in Public Companies.

The audited consolidated net profit of INVL Baltic Farmland, AB amounted to EUR 1,836 thousand, the revenue was EUR 835 thousand for the period of 2024 (for 2023 – consolidated net profit was EUR 2,643 thousand, revenue was EUR 794 thousand). The initial forecast of INVL Baltic Farmland for year 2024 was income of EUR 835 thousand and net profit of EUR 420 thousand. INVL Baltic Farmland had revenue of EUR 835 thousand in 2024 and earned audited net profit of EUR 1,836 thousand for the year. Profit was forecasted under the assumption that the value of agricultural land holdings in the balance sheet would not change and the change in the value of trade receivables by the buyers was not assessed, but a valuation conducted by the company Matininkai showed that land holding value had increased by 9.5% to EUR 22.736 million compared to previous...

Landsbankinn hf.: Landsbankinn finalises acquisition of TM

Written by Customer Service on February 28, 2025. Posted in Public Companies.

Settlement and handover related to the purchase by Landsbankinn of TM tryggingar hf. from Kvika Bank took place today and Landsbankinn has assumed operation of the company. TM will be operated as a subsidiary of Landsbankinn. Lilja Björk Einarsdóttir, CEO of Landsbankinn: “TM is a robust insurance company with great employees who possess extensive knowledge of the insurance market. We look forward to working with TM’s staff to develop exciting innovations. Together, Landsbankinn and TM have a powerful service and sales network, both through experienced employees, digital solutions and branches across the country. We envision strong customer access to the products and services of both companies, creating many growth opportunities for both the Bank and TM. We also believe that the Bank’s acquisition of TM will have a positive impact on the...

Dominion Lending Centres Inc. Announces Closing of $59.15 million Secondary Private Placement Offering of Class A Common Shares

Written by Customer Service on February 28, 2025. Posted in Public Companies.

NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR RELEASE, PUBLICATION, DISTRIBUTION OR DISSEMINATION DIRECTLY, OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO THE UNITED STATES. VANCOUVER, British Columbia, Feb. 28, 2025 (GLOBE NEWSWIRE) — Dominion Lending Centres Inc. (TSX:DLCG) (“DLCG” or the “Corporation”), 2215 Coquitlam Avenue, Port Coquitlam, British Columbia V3B 1J6, along with Mauris Family Investments Inc. (an entity controlled by Gary Mauris), and 603908 B.C. Ltd. (an entity controlled by Chris Kayat and family), announced today that they have closed the previously announced sale of 7,782,400 class “A” common shares (the “Offered Shares”) by the Selling Shareholders (as defined below) at a price of $7.60 per Offered Share for gross proceeds to the Selling Shareholders of approximately $59.15 million (the “Offering”),...

Kvika banki hf.: Sale of TM finalised

Written by Customer Service on February 28, 2025. Posted in Public Companies.

Kvika banki and Landsbankinn have today finalised the sale of 100% of TM tryggingar’s share capital to Landsbankinn. The handover of the insurance company took place simultaneously, with Landsbankinn paying Kvika bank the agreed purchase price upon completion. As previously communicated by Kvika bank on 30 May 2024, the final purchase price has been adjusted based on changes in TM’s tangible equity from the beginning of 2024 until today’s closing date, 28 February 2025. The initially agreed purchase price was ISK 28.6 billion, but the adjusted purchase price amounts to approximately ISK 32.3 billion, reflecting the 2024 purchase price adjustment, and has now been settled. The purchase price may be subject to further modifications, as any changes in TM’s tangible equity from the beginning of the year until the closing date will either be...

UAB “Atsinaujinančios energetikos investicijos“ publishes interim financial statements for the 12-month period of 2024

Written by Customer Service on February 28, 2025. Posted in Public Companies.

UAB “Atsinaujinančios energetikos investicijos” (the Company) publishes its unaudited interim condensed consolidated and separate financial statements for the 12-month period of 2024. Financial results The Company’s objective is to earn a return for the Company’s investors from investments in renewable energy infrastructure facilities and related assets. The main financial indicators for the period were: As at 31 December 2024, the Company’s total assets were EUR 187 855 thousand, total equity was EUR 98 536 thousand, and total liabilities were EUR 89 319 thousand. As at 31 December 2024, the Company’s investment assets at fair value through profit or loss were EUR 157 962 thousand, which compared to 31 December 2023, decreased by EUR 22 098 thousand or 12.27%. The decline in the fair value of the investment portfolio was mainly...

Acme United Reports 10% Increase in Net Sales for the Fourth Quarter of 2024

Written by Customer Service on February 28, 2025. Posted in Earnings Releases And Operating Results.

Net income on an adjusted basis increased 9% in the fourth quarter and 23% for the year SHELTON, Conn., Feb. 28, 2025 (GLOBE NEWSWIRE) — Acme United Corporation (NYSE American: ACU) today announced that net sales for the quarter ended December 31, 2024 were $45.9 million compared to $41.9 million in the fourth quarter of 2023, an increase of 10%. Net sales for the year ended December 31, 2024 were $194.5 million compared to $191.5 million in 2023, an increase of 2%. Excluding the impact of the sale of the Camillus and Cuda hunting and fishing product lines on November 1, 2023, net sales for 2024 increased 6% compared to 2023. Net income for the quarter ended December 31, 2024 was $1.70 million, or $0.41 per diluted share, compared to $1.56 million, or $0.40 per diluted share (as adjusted) for the same period in 2023 an increase...

Financial 15 Split Corp. Extends Termination Date

Written by Customer Service on February 28, 2025. Posted in Dividend Reports And Estimates.

TORONTO, Feb. 28, 2025 (GLOBE NEWSWIRE) — Financial 15 Split Corp. (the “Company”) is pleased to announce it will extend the termination date of the Company a further five year period from December 1, 2025 to December 1, 2030. The term extension allows holders of FTN Class A Shares (“Class A Shares”) to continue to receive ongoing leveraged exposure to a portfolio consisting of high-quality financial services companies made up of Canadian and U.S. issuers, as well as receiving targeted monthly distributions. Since inception of the Company, Class A shareholders have received monthly distributions totaling $26.69 per share. Holders of the FTN.PR.A Preferred Shares (“Preferred Shares”) are expected to continue to benefit from cumulative preferential monthly distributions. The Preferred shareholders have received a total of $12.19...

Praxis Precision Medicines Provides Update on Essential3 and Corporate Update

Written by Customer Service on February 28, 2025. Posted in Earnings Releases And Operating Results.

BOSTON, Feb. 28, 2025 (GLOBE NEWSWIRE) — Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance, today provided an update on the interim analysis for Study 1 of the Essential3 program of ulixacaltamide in essential tremor (ET), an update on other therapies in development and a financial update. Results of the Planned Interim Analysis and Update on Topline Read-out for the Essential3 Program: The Independent Data Monitoring Committee (IDMC) overseeing the interim analysis of Study 1 of the Essential3 program has provided Praxis with the outcome of such analysis. Based on the predefined decision framework for Study 1, the IDMC has recommended...

Oxford Square Capital Corp. Announces Net Asset Value and Selected Financial Results for the Quarter Ended December 31, 2024 and Declaration of Distributions on Common Stock for the Months Ending April 30, May 31, and June 30, 2025

Written by Customer Service on February 28, 2025. Posted in Earnings Releases And Operating Results.

GREENWICH, Conn., Feb. 28, 2025 (GLOBE NEWSWIRE) — Oxford Square Capital Corp. (NasdaqGS: OXSQ) (NasdaqGS: OXSQZ) (NasdaqGS: OXSQG) (the “Company,” “we,” “us” or “our”) announced today its financial results and related information for the quarter ended December 31, 2024.On February 27, 2025, our Board of Directors declared the following distributions on our common stock:Month Ending Record Date Payment Date Amount Per ShareApril 30, 2025 April 16, 2025 April 30, 2025 $0.035May 31, 2025 May 16, 2025 May 30, 2025 $0.035June 30, 2025 June 16, 2025 June 30, 2025 $0.035Net asset value (“NAV”) per share as of December 31, 2024 stood at $2.30, compared with a NAV per share on September 30, 2024 of $2.35.Net investment income (“NII”) was approximately $6.0 million, or $0.09 per share, for the quarter ended December...

Prime Medicine Reports Full Year 2024 Financial Results and Provides Business Updates

Written by Customer Service on February 28, 2025. Posted in Earnings Releases And Operating Results.

— On track to report initial data from Phase 1/2 clinical trial of PM359 for p47phox CGD in 2025 — — IND-enabling studies ongoing for PM577 for Wilson’s Disease; expect to file IND and/or CTA in 1H 2026 — — Additional high-value programs advancing through preclinical development — CAMBRIDGE, Mass., Feb. 28, 2025 (GLOBE NEWSWIRE) — Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, today reported financial results for the full year ended December 31, 2024 and provided a business update. “Entering 2025 marks the next chapter for Prime Medicine as we look to share initial data for our most advanced product candidate, PM359, in chronic granulomatous disease, the only Prime Editor currently in clinical...

Day: February 28, 2025

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals